SABCS 2024 | Biomarker-based chemotherapy optimization for TNBC with PDX models

Jonathan Lei • 12 Dec 2024

SABCS 2024

Breast Cancer

Jonathan Lei, PhD, Baylor College of Medicine, Houston, TX, discusses a preclinical study using patient-derived xenograft (PDX) models to explore biomarkers and molecular mechanisms underlying response to single-agent and combination chemotherapy in triple-negative breast cancer (TNBC). Combination therapies rarely outperformed single agents, with distinct molecular profiles linked to treatment responses. Biomarker-based predictors also demonstrated potential for guiding platinum, taxane, and combination therapies. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.